1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

LLC/MK2 cells

" in MedChemExpress (MCE) Product Catalog:

9573

Inhibitors & Agonists

173

Screening Libraries

338

Fluorescent Dye

233

Biochemical Assay Reagents

856

Peptides

81

MCE Kits

320

Inhibitory Antibodies

1659

Natural
Products

33

Recombinant Proteins

396

Isotope-Labeled Compounds

15

Antibodies

49

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10072A

    Hsp25 kinase inhibitor acetate; MK2 pseudosubstrate acetate

    JNK HSP MAPKAPK2 (MK2) p38 MAPK ERK Others
    MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation [2] .
    <em>MK2</em>-IN-5 acetate
  • HY-12834A
    MK2-IN-1 hydrochloride
    3 Publications Verification

    MAPKAPK2 (MK2) HSP Cancer
    MK2-IN-1 hydrochloride (compound 1) is a potent and selecitve MAPKAPK2 (MK2) inhibitor with an IC50 of 0.11 uM for MK2 and an EC50 of 0.35 uM for pHSP27. MK2-IN-1 hydrochloride impaires the phosphorylation level of serine residues in the Tfcp2l1 protein [2].
    <em>MK2</em>-IN-1 hydrochloride
  • HY-P10072

    Hsp25 kinase inhibitor; MK2 pseudosubstrate

    ERK JNK p38 MAPK HSP MAPKAPK2 (MK2) Others
    MK2-IN-5 is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 targets the protein interaction domain in the MAPK pathway. MK2-IN-5 inhibits HSP25 and HSP27 phosphorylation [2] .
    <em>MK2</em>-IN-5
  • HY-147283

    MAPKAPK2 (MK2) Inflammation/Immunology Cancer
    MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor with an IC50 value of 45 nM. MK2-IN-4 can be used in the research of cancer, inflammation, immunology .
    <em>MK2</em>-IN-4
  • HY-12834

    MAPKAPK2 (MK2) HSP Cancer
    MK2-IN-1 (compound 1) is a potent and selecitve MAPKAPK2 (MK2) inhibitor with an IC50 of 0.11 uM for MK2 and an EC50 of 0.35 uM for pHSP27. MK2-IN-1 impaires the phosphorylation level of serine residues in the Tfcp2l1 protein [2].
    <em>MK2</em>-IN-1
  • HY-131249
    MK2-IN-3
    2 Publications Verification

    MAPKAPK2 (MK2) Inflammation/Immunology
    MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC50s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC50s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo .
    <em>MK2</em>-IN-3
  • HY-112457
    MK2-IN-3 hydrate
    2 Publications Verification

    MAPKAPK2 (MK2) Inflammation/Immunology
    MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC50=0.21 μM), MK-5 (IC50=0.081 μM), ERK2 (IC50=3.44 μM), MNK1(IC50=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2 .
    <em>MK2</em>-IN-3 hydrate
  • HY-W726640

    MAPKAPK2 (MK2) Cardiovascular Disease Metabolic Disease
    Peraquinsin is a MK2 activator. Peraquinsin can be used for the research of vascular disorder or endothelial barrier disorder. Peraquinsin also is an antihypertensive agent .
    Peraquinsin
  • HY-108643

    MAPKAPK2 (MK2) Cancer
    CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent Ki (Ki app) of 330 nM [2].
    CMPD1
  • HY-P3412

    MAPKAPK2 (MK2) Inflammation/Immunology
    MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .
    MMI-0100
  • HY-139553

    ATI-450; CDD-450

    MAPKAPK2 (MK2) Inflammation/Immunology
    Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .
    Zunsemetinib
  • HY-139504

    CC-99677

    MAPKAPK2 (MK2) Inflammation/Immunology
    Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1 .
    Gamcemetinib
  • HY-120111

    MW01-18-150SRM

    p38 MAPK Autophagy Neurological Disease Inflammation/Immunology
    MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .
    MW-150
  • HY-139553A

    (R)-ATI-450; (R)-CDD-450

    Others Inflammation/Immunology
    (R)-Zunsemetinib is the isomer of Zunsemetinib (HY-139553), and can be used as an experimental control. Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .
    (R)-Zunsemetinib
  • HY-120111A

    MW01-18-150SRM hydrochloride

    p38 MAPK Autophagy Neurological Disease Inflammation/Immunology
    MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 hydrochloride (MW01-18-150SRM hydrochloride) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .
    MW-150 hydrochloride
  • HY-151921

    p38 MAPK Inflammation/Immunology
    Anti-inflammatory agent 33 is a potent p38α inhibitor. Anti-inflammatory agent 33 inhibits NO production. Anti-inflammatory agent 33 inhibits LPS-induced iNOS, COX-2, p-p38α, p-MK2 protein expression. Anti-inflammatory agent 33 shows anti-inflammatory activity .
    Anti-inflammatory agent 33
  • HY-13241
    Ralimetinib dimesylate
    10+ Cited Publications

    LY2228820 dimesylate

    p38 MAPK Autophagy Apoptosis Inflammation/Immunology Cancer
    Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.
    Ralimetinib dimesylate
  • HY-107427

    MAPKAPK2 (MK2) p38 MAPK Inflammation/Immunology
    PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC50 of 5.2 nM and a Ki of 3 nM. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) with IC50s of 53 nM and 5.0 nM, respectively. PF-3644022 potently inhibits TNFα production and has anti-inflammatory effect .
    PF-3644022
  • HY-120111B

    MW01-18-150SRM dihydrochloride dihydrate

    p38 MAPK Autophagy Neurological Disease Inflammation/Immunology
    MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .
    MW-150 dihydrochloride dihydrate
  • HY-13241A

    LY2228820

    p38 MAPK Autophagy Inflammation/Immunology Cancer
    Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc .
    Ralimetinib
  • HY-150612

    p38 MAPK Cancer
    (R)-STU104 is a potent and orally active TAK1-MKK3 interaction inhibitor with IC50s of 0.58 μM and 4.0 μM for TNF-α and MKK3 phosphorylation. (R)-STU104 suppresses the TAK1/MKK3/p38/MnK1/MK2/elF4E signal pathways through binding with MKK3 and disrupting the TAK1 phosphorylating MKK3. (R)-STU104 can be used for researching ulcerative colitis .
    (R)-STU104
  • HY-122783

    Antibiotic Cancer
    Isogambogic acid is an antibiotic and anti-cancer agent which efficiently elicit cell death in LLC and SK-LU-1 within a low micromolar range with IC50s of 2.26 μM and 2.02 μM. Isogambogic acid can be used for cancer research .
    Isogambogic acid
  • HY-125443

    Others Cancer
    Lucialdehydes A is a lanostante-type triterpene aldehydes, isolated from the fruiting bodies of Ganoderma lucidum. Lucialdehydes A shows cytotoxic effects on tumor cells, including Lewis lung carcinoma (LLC), T-47D, Sarcoma 180, and Meth-A tumor cell lines .
    Lucialdehyde A
  • HY-122379

    Others Others
    8-Hydroxypinoresinol is a tetrahydrofurofuran lignan that has cytoprotective effects against peroxynitrite-induced LLC-PK1 cell damage .
    8-Hydroxypinoresinol
  • HY-U00433A
    JMV 2959 hydrochloride
    2 Publications Verification

    GHSR Neurological Disease Endocrinology
    JMV 2959 hydrochloride is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32±3 nM in LLC-PK1 cells.
    JMV 2959 hydrochloride
  • HY-154978

    Others Cancer
    Cisplatin-resistant cells-IN-1 (Compound 8) has high cytotoxicity against Cisplatin (HY-17394)-resistant cells. Cisplatin-resistant cells-IN-1 reduces the metabolic activity effectively in the low nanomolar range (IC50: 0.14–1.79 μM in A549/A549-R, K562/K562-R, and MCF-7/MCF-7TamR cells) .
    Cisplatin-resistant <em>cells</em>-IN-1
  • HY-125859A

    MPO

    Bacterial Inflammation/Immunology
    Myeloperoxidase, human white blood cells (MPO) is a peroxidase. In Myeloperoxidase, human white blood cells mediate oxidative stress by promoting the production of reactive oxygen species (ROS) and active nitrogen (RNS), regulating the polarization and inflammation-related signaling pathways of microglia and neutrophils. Myeloperoxidase, human white blood cells has antibacterial activity [2].
    Myeloperoxidase, human white blood <em>cells</em>
  • HY-125664

    Antibiotic Cancer
    Lucialdehyde B is a tetracyclic triterpene isolated from the substrates of Ganoderma lucidum with antiviral and cytotoxic activities. Lucialdehyde B has cytotoxic effects against Lewis lung cancer (LLC), T-47D, Sarcoma 180 and Meth-A tumor cell lines .
    Lucialdehyde B
  • HY-N2757

    Apoptosis Cancer
    7-Ketositosterol is a phytosterol isolated from the fruits of the mulberry tree (Morus alba L.). 7-Ketositosterol can significantly inhibit Cisplatin (HY-17394)-induced apoptosis in LLC-PK1 cells and has the potential to improve Cisplatin-induced nephrotoxicity .
    7-Ketositosterol
  • HY-107430
    Oxythiamine
    2 Publications Verification

    Hydroxythiamin

    Apoptosis Endogenous Metabolite Cancer
    Oxythiamine (Hydroxythiamin), an analogue of anti-metabolite, can suppress the non-oxidative synthesis of ribose and induce cell apoptosis. Oxythiamine is a thiamine antagonist and inhibits transketolase (TK). Oxythiamine inhibits cancer cell apoptosis and inhibits cell proliferation [2] .
    Oxythiamine
  • HY-107430A
    Oxythiamine chloride hydrochloride
    2 Publications Verification

    Hydroxythiamine chloride hydrochloride

    Apoptosis Endogenous Metabolite Cancer
    Oxythiamine (Hydroxythiamine) chloride hydrochloride, an analogue of anti-metabolite, can suppress the non-oxidative synthesis of ribose and induce cell apoptosis. Oxythiamine chloride hydrochloride is a thiamine antagonist and inhibits transketolase (TK). Oxythiamine chloride hydrochloride inhibits cancer cell apoptosis and inhibits cell proliferation [2] .
    Oxythiamine chloride hydrochloride
  • HY-107430B

    Hydroxythiamine chloride

    Apoptosis Cancer
    Oxythiamine (Hydroxythiamine) chloride, an analogue of anti-metabolite, can suppress the non-oxidative synthesis of ribose and induce cell apoptosis. Oxythiamine is a thiamine antagonist and inhibits transketolase (TK). Oxythiamine chloride inhibits cancer cell apoptosis and inhibits cell proliferation [2] .
    Oxythiamine chloride
  • HY-160021

    ROR Inflammation/Immunology
    RORγt agonist 4 (compound 14) is a potent and selective agonist of RORγt. RORγt agonist 4 significantly enhances metabolic stability. RORγt agonist 4 improves the situation of tumor models of mouse B16F10 melanoma and LLC lung adenocarcinoma .
    RORγt agonist 4
  • HY-W008864

    β-Octaacetyllactose

    Antibiotic Fungal Infection
    Lactose octaacetate shows mild to moderate antifungal activity against some fungi, but it has low or no activity against bacteria and yeast. Lactose octaacetate shows low cytotoxicity to MDBK cells, Hep-2 and MDCK cells. Lactose octaacetate has antiviral activity against PV-1 .
    Lactose octaacetate
  • HY-149982

    Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology Cancer
    IDO1-IN-22 (Compound 3) is a IDO1 inhibitor (biochemical hIDO1 IC50: 67.4 nM, HeLa hIDO1 IC50: 17.6 nM). IDO1-IN-22 has excellent antitumor efficacy in LLC xenograft model, as well as desirable pharmacokinetic (PK) profile .
    IDO1-IN-22
  • HY-P3245

    Apoptosis Cancer
    HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells [2] .
    HXR9
  • HY-P3245A

    Apoptosis Cancer
    HXR9 hydrochloride is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 hydrochloride antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 hydrochloride selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells [2] .
    HXR9 hydrochloride
  • HY-125864

    Interleukin Related NF-κB Inflammation/Immunology
    Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases [2] .
    Fibrinogen (Bovine)
  • HY-P0278
    RGD
    5 Publications Verification

    Integrin Cancer
    RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
    RGD
  • HY-P0278A
    RGD Trifluoroacetate
    5 Publications Verification

    Integrin Cancer
    RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.
    RGD Trifluoroacetate
  • HY-13973A
    GSK-3 inhibitor 1
    1 Publications Verification

    GSK-3 Metabolic Disease
    GSK-3 inhibitor 1 (compound core 3) is a GSK-3 inhibitor that induces stem/progenitor cell self-renewal (e.g. induces stem/progenitor cell proliferation while maintaining the ability to differentiate into tissue cells in the progeny) [2].
    GSK-3 inhibitor 1
  • HY-D1727

    Fluorescent Dye Others
    CellTracker Red CMTPX is a cell-permeable fluorescent dye that can be used as a cell tracer for monitoring cell movement and location (Ex/Em=586/614 nm) .
    CellTracker Red CMTPX
  • HY-132202

    PD-1/PD-L1 Apoptosis Cancer
    PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy .
    PD-1/PD-L1-IN-10
  • HY-152237

    IKK Cancer
    TBK1-IN-1 is a potent and selective TANK binding kinase 1 (TBK1) inhibitor with an IC50 value of 22.4 nM. TBK1-IN-1 inhibits TBK1 downstream target genes cxcl10 and ifnβ expression. TBK1-IN-1 has anticancer activity .
    TBK1-IN-1
  • HY-150239

    BAY-299N

    DNA/RNA Synthesis Cancer
    BAY-364 (BAY-299N) is an inhibitor of the second bromine domain in TAF1. BAY-364 inhibits the TAF1 of Kasumi-1 cells, CD34 + cells and K562 cells with IC50 values of 1.0 µM, 10.4 µM and 10.0 µM respectively .
    BAY-364
  • HY-149717

    Others Cancer
    Antitumor agent-122 (Compound 5j) is an antitumor agent with good efficacy, limited toxicity and low resistance. Antitumor agent-122 has antiproliferative activity for MGC-803 cell, HepG2 cell, SKOV3 cell and T24 cell with IC50 values of 5.23 μM, 3.60 μM, 1.43 μM, 3.03 μM, respectively .
    Antitumor agent-122
  • HY-100894

    Caspase Cancer
    Biotin-VAD-FMK is a cell permeable, irreversible biotin-labeled caspase inhibitor, used to identify active caspases in cell lysates.
    Biotin-VAD-FMK
  • HY-122788

    Oleoyl serinol

    Apoptosis Cancer
    N-Oleoyl serinol is a ceramide analog that can be used in stem cell therapy to prevent stem cells from developing into teratomas. N-Oleoyl serinol induces apoptosis in residual pluripotent embryoid body-derived cells (EBCs), prevents teratoma formation, and enriches EBC cells that undergo neural differentiation after transplantation .
    N-Oleoyl serinol
  • HY-158019

    DNA/RNA Synthesis Cancer
    Anticancer agent 196 (compound 1) shows cell cytotoxicity with IC50  values of  7.69 µM and  54.2 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 196 can induce DNA damage .
    Anticancer agent 196
  • HY-158020

    DNA/RNA Synthesis Cancer
    Anticancer agent 197 (compound 2b) shows cell cytotoxicity with IC50  values of  10.03 µM and  73.54 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 197 can induce DNA damage .
    Anticancer agent 197

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: